RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsMaybe this revised statement will be better understood by those "Not many People" detrators ... A "putative" M&A acquisition of ONCY valued at between US$9-10 Billion for ONCY, as a bolt-on acquistion, comfortably falls within Big Pharma's M&A "sweet spot" range of US$5-15 Billion.
Not much has changed, other than the additional evidence which generally supports this estimated acquisition valuation.